CSE:ACOG - Post Discussion
Post by
XeniaTechie on Nov 17, 2021 12:44pm
Watch the Alpha Cognition presentation from the Q4 Investors
Alpha Cognition CEO Michael McFadden presented this morning at the Q4 Investors Summit Group. This was a highly informative session that presented significant lab studies, data and commercialization strategies for their Alpha-1062 treatment which is essentially set to revolutionize the Alzheimer's treatment industry. Tons of upside potential tapping into the $35B ALZ treatment market where 8/10 patients seek treatment and only 4.5/10 stay in treatments due to side-effects of current treatments, A-1062 is in trials and demonstrating strong improvement in side-effect profiles. You can view the recording on-demand, here: https://us06web.zoom.us/webinar/register/WN_5oxO1tQORQKs2TZDYxM-yw
Be the first to comment on this post